Acyl urea compounds have garnered significant attention in cancer therapeutics, particularly for their
potential effectiveness against cancers that predominantly affect women, such as breast and ovarian cancers. The
paper presents a report on the investigation of acyl urea compounds that are reported to involve a multi-faceted
approach, including synthetic chemistry, biological assays, and computational modeling. A wealth of information
on acyl urea and its purported effects on cancer affecting women has been gathered from different sources and
condensed to provide readers with a broad understanding of the role of acyl urea in combating cancer. Acylureas
demonstrate promising results by selectively inhibiting key molecular targets associated with cancer progressions,
such as EGFR, ALK, HER2, and the Wnt/β-catenin signaling pathway. Specifically, targeting acyl ureas impedes
tumor proliferation and metastasis while minimizing harm to healthy tissues, offering a targeted therapeutic approach
with reduced side effects compared to conventional chemotherapy. Continued research and clinical trials
are imperative to optimize the efficacy and safety profiles of acylurea-based therapies and broaden their applicability
across various cancer types. Acyl urea compounds represent a promising class of therapeutics for the treatment
of cancers in women, particularly due to their ability to selectively inhibit key molecular targets involved in
tumor growth and progression. The combination of synthetic optimization, biological evaluation, and computational
modeling has facilitated the identification of several lead compounds with significant anticancer potential.
This abstract explores the therapeutic mechanisms and targeted pathways of acyl ureas in combating these malignancies,
which will be useful for future studies.